Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Ouabain pre-treatment modulates B and T lymphocytes and improves survival of melanoma-bearing animals

2020; Elsevier BV; Volume: 86; Linguagem: Inglês

10.1016/j.intimp.2020.106772

1878-1705

Joyle Moreira Carvalho da Silva, María Luisa Campos, Mariana Pires Teixeira, Renan Faustino, Raul Correia Aleixo, Felipe Jeová Pereira Cavalcante, Lays Ribeiro Oliveira Gomes, Lucas Zanetti de Albuquerque, Augusto das Neves Azevedo, Vinicius Ribeiro Cabral, Luciana Souza de Paiva,

T-cell and B-cell Immunology

Ouabain (OUA) is a glycoside shown to modulate B and T lymphocytes. Nevertheless, ouabain effects on B16F10 melanoma immune response, a mouse lineage that mimics human melanoma, are still unknown. Our aim was to study how OUA in vivo treatment modulates lymphocytes and if it improves the response against B16F10 cells. C57BL/6 mice were pre-treated with intraperitoneal (i.p) injection of OUA (0.56 mg/Kg) for three consecutive days. On the 4th day, 106 B16F10 cells or vehicle were i.p. injected. Animals were euthanized on days 4th and 21st for organs removal and subsequent lymphocyte analyses by flow cytometry. In vivo ouabain-treatment reduced regulatory T cells in the spleen in both melanoma and non-melanoma groups. Ouabain preserved the number and percentage of B lymphocytes in peripheral organs of melanoma-injected mice. Melanoma-injected mice pre-treated with OUA also survive longer. Our findings contribute to a better understanding of OUA immunological effects in a melanoma model.